Hamburg (15. September 2011) – Als häufigste maligne Tumorerkrankung des Mannes nimmt das Prostatakarzinom (PCa) in der Uro-Onkologie einen hohen Stellenwert ein. LHRH-Agonisten und GnRH-Blocker stellen die tragenden Säulen der Androgendeprivationstherapie (ADT) dar. Als GnRH-Blocker blockiert Degarelix die GnRH-Rezeptoren, während LHRH-Agonisten diesen Rezeptor-Typ stimulieren. Aufgrund seines...

Crawford and Hou[1] review the data on luteinizing hormone-releasing hormone (LHRH) antagonists in prostate cancer. They describe the results of a phase III trial comparing monthly degarelix to monthly leuprolide in men with advanced prostate cancer. Degarelix treatment was associated with a more rapid decline of serum testosterone, and was not associated with an initial surge of serum testoste...

PURPOSE We used responses to questionnaires included in the CS21 degarelix trial and published mapping algorithms to address the paucity of evidence for health related quality of life in patients with advanced hormone dependent prostate cancer treated with degarelix. MATERIALS AND METHODS We measured health related quality of life in 610 patients enrolled in the CS21 trial using SF-12® and EO...

background: hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. we performed a systematic review to compare safety, efficacy and effectiveness of degarelix, a new gonadotropin-releasing hormone (gnrh) antagonist (blocker), versus gonadotropin-releasing hormone (gnrh) agonists. methods: medline, web of science and the cochrane library w...

What steps involved in degarelix (Firmagon®, Ferring Pharmaceuticals) administration and patient care do specialist nurses consider most important to reduce the risk of associated injection site reactions, are there any variations materials used support optimal technique? Degarelix is a GnRH antagonist indicated for first-line treatment advanced prostate cancer that effectively suppresses testo...

Medical castration using gonadotropin-releasing hormone (GnRH) receptor agonists currently provides the mainstay of androgen deprivation therapy for prostate cancer. Although effective, these agents only reduce testosterone levels after a delay of 14 to 21 days; they also cause an initial surge in testosterone that can stimulate the cancer and lead to exacerbation of symptoms ("clinical flare")...

Androgen-deprivation therapy (ADT) for prostate cancer has been associated with increased risk for development of cardiovascular events and recent pooled analyses of randomized intervention trials suggest that this primarily is the case for patients with pre-existing cardiovascular disease treated with gonadotropin-releasing hormone receptor (GnRH-R) agonists. In the present study we investigat...

OBJECTIVES To investigate the levels of testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prostate-specific antigen (PSA) in prostate cancer patients before and after the switch from degarelix to leuprolide treatments. METHODS We enrolled 40 treatment-naïve prostate cancer patients who were treated initially with degarelix and were later switched to leuprolide. T...

Introduction A drawback of gonadotropin-releasing hormone (GnRH) antagonist protocols in in vitro fertilization (IVF) is that they have limited flexibility in cycle programming. This proof of concept study explored the efficacy of a single-dose, long-acting GnRH antagonist IVF protocol. Trial registration number is NCT03240159, retrospectively registered on March 08, 2017. Materials and metho...

Several abstracts presented at the 2015 European Association of Urology Meeting highlighted new developments in hormone therapy for prostate cancer management. One abstract described how the luteinizing hormone-releasing hormone (LHRH)/gonadotropin-releasing hormone (GnRH) agonist leuprolide, but not the LHRH/GnRH antagonist degarelix, induced plaque instability in a mouse model. A second abstr...